Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.

Advances in Therapy
Shang-Yi HuangChang-Ki Min

Abstract

The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for time to first on-study SREs. Here we present a subgroup analysis to evaluate efficacy and safety in Asian patients. Patients were randomized 1:1 to receive denosumab 120 mg subcutaneously or zoledronic acid intravenously 4 mg every 4 weeks in a double-blind, double-dummy fashion. All patients received standard-of-care first-line antimyeloma treatment. Each patient received either study drug until an estimated 676 patients experienced at least one on-study SRE and the primary efficacy and safety analyses were completed. Of 1718 total enrolled patients, 196 Asian patients (denosumab, n = 103; zoledronic acid, n = 93) were included in this subgroup analysis. Fewer patients in the denosumab group developed first on-study SRE compared with the zoledronic acid group; the crude incidence of SREs at the primary analysis cutoff was 38.8% and 50.5%, respectively (HR [95% CI], 0.77 [0.48-1.26]). All 194 patients receiving at least one dose of study drug exper...Continue Reading

References

Apr 16, 2004·The New England Journal of Medicine·G David Roodman
May 26, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E TerposUNKNOWN European Myeloma Network
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H HenryHoward Yeh
Sep 15, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Allan LiptonSusie Jun
Oct 29, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·David HenryHoward Yeh
Apr 12, 2014·American Journal of Hematology·Kihyun KimBrian G Durie
Jul 13, 2016·International Journal of Clinical Oncology·Mutsushi YamasakiJunji Yonese
Aug 7, 2017·Internal Medicine Journal·Oi Lin LeeAndrew Zannettino
Dec 19, 2017·The Cochrane Database of Systematic Reviews·Rahul MhaskarBenjamin Djulbegovic
Jan 14, 2018·Blood Cancer Journal·Evangelos TerposMeletios A Dimopoulos
Jan 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kenneth AndersonRobert A Kyle
Jun 30, 2018·Cancer Epidemiology·Chao-Hsiun TangYanfang Liu
Oct 5, 2018·Expert Review of Hematology·Nikolaos KanelliasMeletios Athanasios Dimopoulos
Dec 12, 2019·Journal of Hematology & Oncology·Jiangmei LiuUNKNOWN Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology

❮ Previous
Next ❯

Methods Mentioned

BETA
ISS

Clinical Trials Mentioned

NCT01345019

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.